Advisor Group Holdings, Inc. Cyma Bay Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$12.63 - $24.47 $194,956 - $377,718	15,436 Added 370.97%	19,597 $462,000
Q3 2023 Nov 13, 2023	SELL	$10.86 - $17.62 $28,594 - $46,393	-2,633 Reduced 38.75%	4,161 $62,000
Q2 2023 Aug 10, 2023	BUY	$7.47 - $10.95 $4,063 - $5,956	544 Added 8.7%	6,794 $74,000
Q3 2021 Nov 05, 2021	BUY	$3.47 - $4.42 $21,687 - $27,625	6,250 New	6,250 $23,000
Q2 2021 Aug 02, 2021	SELL	$3.94 - $4.92 $3,940 - $4,920	-1,000 Closed	0 $0

Q1 2021 May 13, 2021	BUY	$4.23 - $6.55 $4,230 - $6,550	1,000 New	1,000 $5,000
Q4 2020 Feb 10, 2021	SELL	$5.73 - $9.03 $11,460 - $18,060	-2,000 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$3.32 - $7.24 $6,640 - $14,480	2,000 New	2,000 $14,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.